Molecular Imaging of Biomarkers in Breast Cancer

Ulaner, Gary A.; Riedl, Christopher C.; Dickler, Maura N.; Jhaveri, Komal; Pandit‐Taskar, Neeta; Weber, Wolfgang

doi:10.2967/jnumed.115.157909

Cited by 62 publications

(55 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, differences across studies in definitions of pathological response, time points for interim 18 F-FDG-PET/CT evaluations, and 18 F-FDG uptake thresholds for response, have prevented clinical translation of interim 18 F-FDG-PET/CT evaluation in breast cancer patients. 47,49,88 18 F-FDG-PET/CT evaluation of NAT response has yet to gain wide acceptance due to limited accuracy and specificity of the technique; these limitations have been attributed to significant differences in 18 F-FDG uptake between breast cancer subtypes, both at baseline and after treatment. 48–50,88 While the ability of 18 F-FDG-PET/CT to predict NAT response may be receptor status dependent and requires further investigation, the technique shows promise for early evaluation and prediction of response to NAT prior to downstream alterations in tumor size.…”

Section: Emerging Strategiesmentioning

confidence: 99%

Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting

Sorace¹,

Harvey²,

Syed³

et al. 2017

Seminars in Oncology Nursing

View full text Add to dashboard Cite

Objective To discuss standard-of-care and emerging imaging techniques employed for screening and detection, diagnosis and staging, monitoring response to therapy, and guiding cancer treatments. Data Sources Published journal articles indexed in the National Library of Medicine database and relevant websites. Conclusion Imaging plays a fundamental role in the care of cancer patients and specifically, breast cancer patients in the neoadjuvant setting, providing an excellent opportunity for interprofessional collaboration between oncologists, researchers, radiologists and oncology nurses. Quantitative imaging strategies to assess cellular, molecular, and vascular characteristics within the tumor is needed to better evaluate initial diagnosis and treatment response. Implications for nursing practice Nurses caring for patients in all settings must continue to seek education on emerging imaging techniques. Oncology nurses provide education about the test, ensure the patient has appropriate pre testing instructions, and manage patient expectations about timing of results availability.

show abstract

Section: Emerging Strategiesmentioning

confidence: 99%

Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting

Sorace¹,

Harvey²,

Syed³

et al. 2017

Seminars in Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…If MBI is to ultimately function as a primary screening modality for pinpointing the early biochemical changes arising within an occult breast cancer, it must be paired with plasma and/or urine biomarkers indicating a metabolic pathway amenable to clinical imaging is aberrantly upregulated within a malignant breast tumor [8].…”

Section: Introductionmentioning

confidence: 99%

Imaging Cobalamin Uptake within Malignant Breast Tumors In Vivo

Collins

2018

Mol Imaging Biol

View full text Add to dashboard Cite

“…Mammary tumors present highly complexity and heterogeneity, while global understanding of the underlined molecular mechanisms governing their origin and progression is still lucking [12]. Molecular imaging has been considered to exert a promising role in complementing and overcoming some of the limitations of traditional biomarkers by providing the ability to perform noninvasive, repeatable whole-body assessments [13]. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) define prognosis and identify tumors for targeted therapy, and remain the sole established single-molecule biomarkers defining the minimum breast cancer pathology data set [14].…”

Section: Introductionmentioning

confidence: 99%

Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients

Giaginis

Sampani

Kotta-Loizou

et al. 2017

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells' proliferative capacity and overall and disease-free patients' survival. High HuR expression was positively associated with larger tumor size and advanced disease stage (p = 0.0234 and p = 0.0361, respectively), being more frequently observed in ER negative cases (p = 0.0208). High COX-2 expression was negatively associated with histological (p < 0.0001) and nuclear (p = 0.0033) grade and tumor cells' proliferative rate (p = 0.0015), being more frequently observed in luminal-A compared to other molecular subtypes (p = 0.0221). High HuR expression was associated with poor overall and disease-free patients' survival at both univariate (log-rank test, p = 0.0092 and p = 0.0004, respectively) and multivariate (Cox-regression analysis, p = 0.0223 and p = 0.0004, respectively) level. On the other hand, high COX-2 expression was associated with favorable overall and disease-free patients' survival merely at univariate level (log-rank test, p = 0.0389 and p = 0.0154, respectively). HuR expression was not associated with COX-2 expression (Spearman R = 0.1489, p = 0.1032). The present data support evidence that HuR is associated with tumor aggressiveness and poor prognosis in breast carcinoma, reinforcing its potential as promising therapeutic target in this type of neoplasia.

show abstract

Molecular Imaging of Biomarkers in Breast Cancer

Cited by 62 publications

References 85 publications

Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting

Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting

Imaging Cobalamin Uptake within Malignant Breast Tumors In Vivo

Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients

Contact Info

Product

Resources

About